Immune response to a recombinant human TNFR55-IgG1 fusion protein: Auto- antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities

Human Immunology

Volumn 60, Issue 9, 1999, Pages 774-790

  Christen, Urs ^a   Thuerkauf, Rana ^a   Stevens, Randall ^b   Lesslauer, Werner ^b  

^a Preclinical Research   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Autoimmunity; Clinical trial; Epitope mapping; Rheumatoid factor; TNRF IgG fusion protein

Indexed keywords

AUTOANTIBODY; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M ANTIBODY; LENERCEPT; RECOMBINANT TUMOR NECROSIS FACTOR; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREACTIVITY; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIGENS, CD; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CELLS, CULTURED; CHROMATOGRAPHY, AFFINITY; ENDOTHELIUM, VASCULAR; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; HL-60 CELLS; HUMANS; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE-1; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; RECEPTORS, FC; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; UP-REGULATION;

EID: 0032832138     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00068-3     Document Type: Article

References (34)

1. Elliot M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., Woody J.N. Randomised double blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105.
2. Raine C.S. Multiple sclerosis TNF revisited, with promise . Nature Med. 1:1995;211.
3. Lesslauer W. Fc fusion proteins TNFα receptor IgG, design principles and activities . Chamow S., Ashkenazi A. Antibody fusion proteins. 1999;J. Wiley & Sonc, Inc, New York.
4. Lesslauer W., Tabuchi H., Gentz R., Brockhaus M., Schlaeger E.J., Grau G., Piguet P.E., Pointaire P., Vassalli P., Loetscher H. Recombinant soluble tumor necrosis factor receptor protect mice from lipopolysaccharide lethality. Eur J Immunol. 21:1991;2883.
5. Ashkenazi A., Marsters S.A., Capon D.J., Chamow S.M., Figari I.S., Pennica D., Goeddel D.V., Palladino M.A., Smith D.H. Protection against endotoxic shock by tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA. 88:1991;10535.
6. Cutolo M, Kirkham B, C. B, Sany J, Scott D, Brooks P, Forre O, Jain R, Kvien T, Markenson J, Seibold J, Sturrock R, Veys E, Edwards J, Zaug M, Durrwell L, Bisschops C, St. Clair P, Milnarik P, Baudin M, Van der Auwera P: Loading/maintenance doses approach to neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of double-blind placebo controlled phase II trial. Arthritis & Rheumatism, 39 (9), Supplement:S243, 1996.
7. Furst D, Weisman M, Paulus H, Bulpitt K, Weinblatt M, Polisson R, St. Clair P, Milnarik P, Baudin M, Luedin E, McAuliffe T, Kaehny M-R, Lesslauer W, Van der Auwera P: Neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of an US phase II trial. Arthritis & Rheumatism, 39 (9), Supplement:S243, 1996.
8. Hasler F, van de Putte L, Baudin M, Luedin E, Durrwell L, McAuliffe T, Van der Auwerea P: Chronic TNF neutralization (up to 1 year) by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis: results of an open-label extension of a double-blind single dose phase I study. Arthritis & Rheumatism, 39 (9), Supplement:S243, 1996.
9. Hasler F, van de Putte L, Dumont E, Kneer J, Bock J, Dickinson S, Lesslauer W, Van der Auwera P: Safety and efficacy of TNF neutralization by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis exposed to a single dose. Arthritis & Rheumatism, 39 (9), Supplement:S243, 1996.
10. Rau R, Sander O, Schattenkirchner M, Baudin M, Siehr U, Bisschops C, Van der Auwera P: Monthly vs. bimonthly dosing of Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatois arthritis treated for 3 months: results of a double-blind controlled phase II trail. Arthritis & Rheumatism, 39 (9), Supplement:S243, 1996.
11. Sander O, Rau R, van Riel P, van de Putte L, Hasler F, Baudin M, Luedin E, McAuliffe T, Dickinson S, Kaehny M-R, Lesslauer W, Van der Auwera P: Neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a european phase II trial. Arthritis & Rheumatism, 39 (9), Supplement:S242, 1996.
12. Christen U, Baudin M, Birnboeck H, Dumont E, Gallati H, Loetscher H, Zaug M, Lesslauer W: Preliminary report on the anti-Ro 45-2081 antibody response in rheumatoid arthritis patients of studies BK 14680 and BM 14752. Roche Research Report No. B-166'394, 1996.
13. Mackay F., Loetscher H., Stueber D., Gehr G., Lesslauer W. Tumor necrosis factor α (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med. 177:1993;1277.
14. Brockhaus M., Schoenfeld H.-J., Schlaeger E.J., Hunziker W., Lesslauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA. 87:1990;3127.
15. Gallati H, Pracht I: TNFR 55 hg 1 (Ro 45-2081): Six enzyme immunoassays for detection and quantification of human and animal antibodies to the different parts of the TNFR 55 hg 1 construct. Roche Research Report No. B-162'830, 1995.
16. Christen U, Thuerkauf R, Lesslauer W: Binding of TNFR55-IgG1 (Tenefuse, Lenercept, Ro 45-2081) to human cells. Roche Research Report No. B-169'135, 1998.
17. Debets J.M.H., Van de Winkel J.G.J., Ceuppens J.L., Dieteren I.E.M., Buurman W.A. Cross-linking of both FcγRI and FcγRII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-FcγR interactions. J Immunol. 144:1990;1304.
18. Fanger M.W., Shen L., Graziano R.F., Guyre P.M. Cytotoxicty mediated by human Fc receptors for IgG. Immunol Today. 10:1989;92.
19. Hoffmann T., Tripathi A.K., Lee Y.L., Bonvini E., Golding B. Inflammatory mediator release from human monocytes via immobilized Fc receptor. Transplantation. 54:1992;343.
20. Macintyre EA, Roberts PJ, Jones M, Van der Schoot CE, Favalaro EJ, Tidman N, C. LD: Activation of human monocytes occurs on cross-linking monocytic antigens to an Fc receptor. J Immunol 142:2377, 1989.
21. Szabo G., Kodys K., Miller-Graziano C.L. Elevated monocyte interleukin-6 (IL-6) production in immunosuppressed trauma patients. I. Role of FcγRI cross-linking stimulation. J Clin Immunol. 11:1991;326.
22. Loetscher H., Pan Y.-C.E., Gentz R., Brockhaus M., Tabuchi H., Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 61:1990;351.
23. Terness P., Navolan D., Kohl I., Siedler F., Moroder L., Dufter C., Welschof M., Schneider F., Drugarin D., Opelz G. Role of idiotype-independent anti-IgG autoantibodies in human kidney transplantation natural anti-F(ab′)2 antibodies recognize and IgG1 hinge region peptide . Transplant Proceed. 29:1997;1412.
24. Welschof M., Terness P., Kipriyanov S.M., Stanescu D., Breitling F., Doersam H., Duebel S., Little M., Opelz G. The antigen-binding domain of a human IgG-anti-F(ab′)2 autoantibody. Proc Natl Acad Sci USA. 94:1997;1902.
25. Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.-J., Broger C., Loetscher H., Lesslauer W. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex implications for TNF receptor activation . Cell. 73:1993;431.
26. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., Coats M.E., Goodkin D.E., Weinstock-Guttman B., Herndon R.M., Mass M.K., Richert J.R., Salazar A.M., Munschauer F.E. III, Cookfair D.L., Simon J.H., Jacobs L.D. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. 50:1998;1266.
27. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b Experiences during the first three years . Neurology. 47:1996;889.
28. Runkel L., Meier W., Pepinsky R.B., Karpusas M., Whitty A., Kimball K., Brickelmaier M., Muldowney C., Jones W., Goelz S.E. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm Res. 15:1998;641.
29. Berzofsky J.A., Berkower I.J. Immunogenicity and antigen structure. Paul W.E. Fundamental Immunology. 1993;Raven Press Ltd, New York.
30. Novotny J., Handschumacher M., Haber E., Bruccoleri R.E., Carlson W.B., Fanning D.W., Smith J.A., Rose G.D. Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). Proc Natl Acad Sci USA. 83:1986;226.
31. Naismith J.H., Devine T.D., Kohno T., Sprang S.R. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure. 4:1996;1251.
32. Chen W., Peace D.J., Rovira D.K., You S.-G., Cheever M.A. T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA. 89:1992;1468.
33. Kaufmann D.L., Claire-Alzler M., Tian J., Forsthuber T., Ting G.S.P., Robinson P., Atkinson M.A., Sercarz E.E. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature. 366:1993;69.
34. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T-cell autoimmunity to cyptic determinants of an autoantigen. Nature. 358:1992;155.